The Diabetes and Thyroid Center of Fort Worth Clinical Research Department is committed to providing excellent clinical research support for our patients and our practice community. Our mission is to provide our patients with access to the newest medications and best options available in the treatment of their conditions. DTC has participated in many important clinical trials in the field of type 2 diabetes and lipid therapy.
We are always looking for study participants and currently enrolling for multiple clinical trials.
Clinical Trial Research
Download Research New Patient Packet
If you are interested in participating or think you may qualify for one of the trials listed below, please contact our research team. Call us at 817-779-4478 or email research@dtc-fw.com. We would be happy to provide you with more information or complete an evaluation!
OUR CURRENT ENROLLING TRIALS
- CYPRESS – A Phase 2 Study of RTA901 in Patients with Peripheral Neuropathic Pain
CLICK HERE
- ACHIEVE-3 – A Phase 3 Open-Label Study to Investigate the Efficacy and Safety of Once Daily LY3502970 Compared with Oral Semaglutide in Adult Patients with Type 2 Diabetes and Inadequate Glycemic Control with Metformin
CLICK HERE - A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)
CLICK HERE
- Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas (GRADIENT)
CLICK HERE
- ZEUS – A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation (ZEUS)
CLICK HERE
- REDEFINE 3: A Research Study to See the Effects of CagriSema on Heart Disease in People Living With Obesity and Diseases in the Heart and Blood Vessels (REDEFINE 3)
CLICK HERE
- A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)
CLICK HERE
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants wit Body Mass Index >=27 kg/m2 and Atherosclerotic Cardiovascular Disease and/or Kidney Disease (TRIUMPH-Outcomes Trial)
CLICK HERE
- Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies (TANDEM)
CLICK HERE
- A Phase 2 Trial of BMF-219 in Participants with Type 1 Diabetes Mellitus
CLICK HERE
- A research study to see how well new weekly medicine IcoSema, which is a combination of insulin icodec and semaglutide, controls blood sugar levels in people with type 2 diabetes, compared to daily insulin glargine (COMBINE 4)
More Information Coming Soon
- A research study on the efficacy and safety of Armour Thyroid Treatment in Subjects with Primary Hypothyroidism
More Information Coming Soon